Biotech Values

[walldiver]

re ONXX...

One thing about sorafenib is that it will be pretty difficult to demonstrate a survival benefit in its Phase 3. The DSMB halted the trial in March after the progression benefit was shown to be stat sig, and the placebo patients were granted access to the drug. Either way, there is not much doubt about sorafenib getting approved next quarter.